Core Viewpoint - Shanghai Xitai Li Biopharmaceutical Technology Co., Ltd. has made significant progress in the Phase I clinical trial of its first-in-class weight loss/metabolic drug XTL6001, marking a key leap for Chinese pharmaceutical companies in the global weight loss sector [1][3]. Group 1: Clinical Trial Progress - The first single ascending dose (SAD) group showed good safety, and the second SAD dose group was successfully administered on July 7, 2025 [1]. - The overall progress of the project is in line with expectations, indicating a successful transition from mechanism innovation to clinical validation [1]. Group 2: Innovative Mechanism - XTL6001 features a unique GLP-1/GCG/novel target three-pathway synergistic mechanism, addressing key limitations of current mainstream GLP-1 drugs [3]. - The drug significantly reduces gastrointestinal side effects, with preclinical data showing an adverse reaction rate related to vomiting close to zero, potentially overcoming the 74% incidence of nausea and vomiting seen with existing therapies [3]. - It offers dual benefits of weight loss and muscle protection, breaking the traditional therapy's issue of muscle loss [3]. - The drug promotes physiological appetite regulation, avoiding excessive suppression of appetite and fostering a more natural balance of appetite and metabolism [3]. Group 3: Inclusion Criteria for Clinical Trial - The trial strictly selected healthy participants aged 18-65 years with a BMI of 18.5-28.0 kg/m², with specific weight requirements for males (≥50.0 kg) and females (≥45.0 kg) [3].